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Whereas in many parts of the world a low protein diet (LPD, 0.6-0.8 g/kg/day) is routinely prescribed for the
management of patients with non-dialysis-dependent chronic kidney disease (CKD), this practice is infrequent
in North America. The historical underpinnings related to LPD in the USA including the non-conclusive results
of the Modification of Diet in Renal Disease Study may have played a role. Overall trends to initiate dialysis
earlier in the course of CKD in the US allowed less time for LPD prescription. The usual dietary intake in the
US includes high dietary protein content, which is in sharp contradistinction to that of a LPD. The fear of
engendering or worsening protein-energy wasting may be an important handicap as suggested by a pilot
survey of US nephrologists; nevertheless, there is also potential interest and enthusiasm in gaining further
insight regarding LPD’s utility in both research and in practice. Racial/ethnic disparities in the US and patients’
adherence are additional challenges. Adherence should be monitored by well-trained dietitians by means of
both dietary assessment techniques and 24-h urine collections to estimate dietary protein intake using urinary
urea nitrogen (UUN). While keto-analogues are not currently available in the USA, there are other oral
nutritional supplements for the provision of high-biologic-value proteins along with dietary energy intake of
30–35 Cal/kg/day available. Different treatment strategies related to dietary intake may help circumvent the
protein- energy wasting apprehension and offer novel conservative approaches for CKD management in
North America.
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Prescribing and reinforcing a low protein diet (LPD)
as a means of conservatively managing chronic kidney
disease (CKD) progression is not largely practiced in
North America. This may be due to a variety of rea-
sons including lack of strong evidence about the effi-
cacy and safety of such dietary approaches, especially
in populations with preexisting nutritional challenges* Correspondence: kkz@uci.edu
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represent a growing proportion of patients with CKD.
Additionally, the inconclusive results from a large US
randomized trial in the early 1990’s, the Modification
of Diet in Renal Disease (MDRD) study [1], played a
key role to this end. Another likely reason is that
many nephrologists in the USA and Canada lack the
needed education, insight, and prior training and ex-
perience related to LPD, while they are exceptionally
well trained to prepare CKD patients for the transi-
tion to conventional (full-dose) dialysis treatment.
The rise of the dialysis industry and recommendations
by nephrology guidelines to initiate dialysis earlier ra-
ther than later have each contributed to these trends
over the past two decades. Fear of what used to bele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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“malnutrition-inflammation cachexia syndrome,” is
another potential barrier, especially since among the
many various complications of CKD those affecting
nutritional status including both loss of structural
(muscle mass loss) and visceral proteins (hypoalbu-
minemia) are among the strongest predictors of poor
outcomes [2, 3].
Given the above conditions and concerns, the question
remains as to why should we revisit the use of LPD for
the conservative management of CKD in North America.
A recent trial suggested that there was no survival benefit
in starting patients earlier on dialysis [4]. This landmark
study, supported by an increasing number of observational
data in recent years, have paved the way for revisiting
more conservative approaches in managing patients with
advanced CKD who may prefer to avoid dialysis as long as
possible [5]. Nevertheless, the concern about PEW along
with inadequate training for the conservative management
of CKD are two important barriers for bringing the LPD
back to North America.
Dietary protein intake in Americans with and
without CKD
The designation of the LPD that is recommended for
the management of CKD refers to a dietary protein
intake of 0.6 to 0.8 grams of protein per kilogram of
ideal body weight per day (g/kg/day). This amount is
currently much lower than what is consumed in the
USA. It is important to note that according to the Food
and Nutrition Board (FNB) of the National Academy of
Sciences of the USA, the minimum dietary protein re-
quirement of a normal healthy (non-pregnant, non-
lactating) adult person is indeed 0.6 g/kg/day; however,
the FNB has stipulated adding a 33 % safety margin to
this minimum amount, so that the “Recommended
Dietary Allowance” (RDA) for healthy adults is to be
0.8 g/kg/day [6]. Hence, because a diet restricted to
0.6 g/kg/day protein intake is 25 % below the recom-
mended 0.8 g/kg/day, the term “LPD” has generally
been used to describe it, as it can be argued that giv-
ing 25 % less protein on a long-term basis might be
inadequate for certain periods of time where the body
is in an anabolic state (e.g. recovery from illnesses or
injuries) [6]. For a stable (e.g. non-nephrotic, non-
inflamed/non-catabolic) NDD-CKD patient, the so-called
LPD of 0.60–0.80 g/kg/day represents sufficient protein
intake—especially because the diet prescription includes
the stipulation that 50 % of the protein should be of high
biological value (see below).
According to a recent study by Moore et al. [7] who
examined the pattern of dietary protein intake in the
general population in the USA, an average American
currently eats 1.3 g/kg/day. In this study theinvestigators examined dietary data from 16,872 adults
(>20 years) who had participated in a contemporary
phase of the National Health and Nutrition Examination
Survey (NHANES) in the USA between 2001 and 2008
and who had completed a dietary interview and a 24-h
diet recall [7]. According to these data, US women and
men eat on average 1.25 and 1.36 g/kg/day of protein,
respectively (see Fig. 1). Across race and ethnicity, His-
panics reported the highest dietary protein intake of
1.43 g/kg/day, while blacks exhibited the lowest amount at
1.24 g/kg/day. Dietary protein intake declined across
advancing categories of age (see Fig. 1), but notably
was still >1 g/kg/day even for those over 75 years of
age.
These data should be juxta-positioned to a typical
LPD of 0.6 to 0.8 g/kg/day. Indeed the strict form of
LPD is expected to have a protein content closer to
0.6 g/kg/day with only less than +/−0.1 g/kg/day vari-
ation [7]. At least half of this amount should be of
high biologic value (HBV) protein, such as those pro-
vided by animal and dairy products, to assure
provision of essential amino acids. The “biological
value” (BV) is the ratio of nitrogen incorporated into
the body over nitrogen absorbed. BV is different from
absorbability or bioavailability (i.e., how readily the
protein can be digested and absorbed by the intestinal
tract). Amino acid composition is the most important
factor, as essential amino acids (EAA) missing from
the diet prevent the synthesis of proteins that require
them. If a protein source is missing EAAs, then its
biological value will be low, as the missing EAAs
form a bottleneck in protein synthesis (see Table 1).
Given the above data, the average US citizen consumes
a diet that is twice the amount of protein recommended
for the management of CKD. It is important to note that
with progressive decline in glomerular filtration rate
(GFR), an unconscious decrease in dietary protein and en-
ergy intake is often observed in CKD patients [8]. This
dietary decline is considered to be the result of the natural
progression of CKD, especially when the estimated GFR
(eGFR) falls below 25 ml/min/1.73 m2; hence, it is feared
that such a decline in dietary protein intake may be
accompanied by worsening nutritional status (see below)
[9]. Although, most patients with CKD consume less
dietary protein, the analyses of the NHANES data by
Moore et al. [7] showed that after adjusting for age, the
mean dietary protein intake of participants with CKD in
the US was still high at 1.30 g/kg/day and did not differ
between CKD Stages 1 and 2, i.e., 1.28 and 1.25 g/kg/day,
respectively. Furthermore, although dietary protein intake
was significantly different in Stages 3 and 4, i.e., 1.22 and
1.13 g/kg/day, respectively (see Fig. 2), it still remained
well above the aforementioned LPD of 0.6 to 0.8 g/kg/day
for Stages 3 and 4 CKD.
Table 1 Biologic value of selected protein-rich foods. On a scale with 100 representing the highest efficiency. Foods with high
biologic value (HBV) need to have a total score >75 (Source: Wikidoc on line: www.wikidoc.org/index.php/Biological_value)
Ile Leu Val Thr Met & Cys Trp Lys Phe & Tyr His Biologic value
Whole egg 1 1 1 1 1 1 1 1 1 95
Milk, human 1.1 1.4 1 1 1.1 1.6 1 1 0.9 95
Milk, cow 1.1 1.3 1 0.9 0.7a 1.3 1.3 0.9 1.1 90
Muscle, beef 0.8 0.9 0.7 0.9 0.9 0.9 1.4 0.7a 1.6 76
Soybeans 1.0 0.9 0.8 0.8 0.6a 1.3 1.1 1.0 1.4 75a
Rice 0.8 0.9 0.9 0.8 0.9 1.2 0.5a 1.2 0.8 75a
Wheat 0.6 0.8 0.6 0.7 0.8 1.1 0.4 0.8 1 67a
Potatoes 0.6 1.1 0.8 1.3 0.6 1.9 1.4 0.8 1.1 67a
Oats 0.8 0.8 0.8 0.7a 0.6a 1.2 0.6a 1 1.1 66a
Corn 1 1.7 0.8 0.7a 1.1 0.5a 0.4a 1 1 60a
Amino-acid abbreviations: Ile Isoleucine, Leu Leucine, Thr Threonine, Met Methionine, Cys Cysteine, Trp Tryptophan, Lys Lysine, Phe Phenylalanine,
Tyr Tyrosine, His Histidine
aindicate low biologic value
Fig. 1 Estimated DPI in the USA across gender, race, and age; normalized to protein in g/kgIBW/d, for adults in the USA depicted for (a) sex, (b)
race or ethnicity, and (c) age group. Analysis of variance for each panel, p<0.0001. Per panel, pairwise comparisons with each reference (ref)
group: *p<0.0001, †p<0.01. Adapted from secondary NHANES data analyses by Moore et al. (with permission) [7]
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Fig. 2 Estimated DPI in the USA across gender, race, and age
accounting for stages of CKD: normalized to protein in g/kgIBW/d, for
adults in the USA depicted for (a) sex, (b) race or ethnicity, and (c) age
group. No evidence of CKD (No CKD), stage 1 CKD (eGFR, ≥90ml/min
with kidney damage), stage 2 CKD (eGFR 60–89ml/min with kidney
damage), stage 3 CKD (eGFR 30–59ml/min), or stage 4 CKD (eGFR <30
ml/min without dialysis). Overall FANOVA for each panel, P<0.0001. Per
panel, pairwise comparisons with each reference group: *P<0.0001,
†P<0.05. Per panel, pairwise comparisons with each subgroup ((a)
females at each stage of CKD compared with NoCKD and males at
each stage of CKD compared with NoCKD; (b) NH black at each stage
of CKD compared with NoCKD, Mexican American or Latino at each
stage of CKD compared with NoCKD, and NH white at each stage of
CKD compared with NoCKD; (c) 20–54-year-olds at each stage of CKD
compared with NoCKD, 55–64-year-olds at each stage of CKD
compared with NoCKD, 65–74-year-olds at each stage of CKD
compared with NoCKD, and 75+-year-olds at each stage of CKD
compared with NoCKD): ‡P<0.0001, §P<0.001, ||P<0.01, ¶P<0.05.
Adapted from secondary NHANES data analyses by Moore et al.
(with permission) [7]
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An important challenge for reinvigorating enthusiasm
for the LPD in the USA is the fear of PEW. There islittle doubt that PEW is more likely to occur in later
stages of CKD, especially when the eGFR is <25 ml/min/
1.73 m2. To differentiate between various causes and
consequences of the wasting syndrome in CKD, it is
important to systematically define what is meant under
the older designation of “protein-energy malnutrition.”
[10] A working definition was advanced by Kalantar-
Zadeh et al. in [11] as “the state of decreased body pools
of protein with or without fat depletion or a state of
diminished functional capacity, caused at least partly by
inadequate nutrient intake relative to nutrient demand
and/or which is improved by nutritional repletion.” We
believe that this definition is applicable across all stages
of CKD and encompasses what is also more recently
referred to as PEW [11]. Hence, uremic malnutrition or
wasting is engendered when the body’s need for protein
and/or energy fuels cannot be satisfied by usual dietary
intake.
Different conditions may contribute to PEW in
CKD patients as discussed elsewhere [12]. In a recent
study of 1,220 non-dialysis CKD patients by Kovesdy
et al. [13], 45 % of participants had a serum albumin
<3.8 g/dL and 22 % of subjects had a level <3.4 g/dL.
Furthermore, the probability of PEW (defined as the
presence of two or more out of three biochemical
markers of PEW) showed a significant and linear in-
crease with lower levels of eGFR [13]. In another
study by Lawson et al. [14] in 50 CKD patients with
serum creatinine >1.7 mg/dL, it was demonstrated
that 20 % of patients were mildly-to-moderately mal-
nourished, and 8 % were severely malnourished.
Other similar studies including an analysis by Molnar
et al. using the “malnutrition-inflammation score”
have reported similar prevalences [15].
Adjusting and monitoring dietary protein intake
in CKD
Various renal nutrition guidelines [16, 17] recommend
the achievement of certain thresholds of dietary protein
intake in patients with moderate to advanced CKD with
the goals of preventing the development of PEW or
treating established PEW. The so-called “low” (LPD) and
“very low protein diets” (VLPD) represent a daily protein
intake of ~0.6 and ~0.3 g/kg/day [6]. Whereas the latter
is very difficult to achieve and may be more likely
associated with PEW risk, the former appears more
practical and less risky. Many practicing nephrologists
recommend a daily protein intake of 0.6 to 0.8 g/kg/day
and monitor the adherence by estimating it (eDPI)
using 24-h urinary urea nitrogen (UUN) where 1 g UN
represents 6.25 g of protein and non-urea nitrogen
excretion of 30 mg/kg/day [18] along with urinary
protein losses if >5 g/day:
Table 2 Excerpts of the Kidney Disease Outcome Quality
Initiative (KDOQI) guidelines regarding dietary protein intake in
diabetic kidney disease, developed by the by the National
Kidney Foundation (NKF) of the USA 2007 [24]
KDOQI Clinical Practice Guidelines and Clinical Practice
Recommendations for Diabetes and Chronic Kidney Disease, 2007
GUIDELINE 5: NUTRITIONAL MANAGEMENT IN DIABETES AND CHRONIC
KIDNEY DISEASE
Management of diabetes and CKD should include nutritional
intervention. Dietary modifications may reduce progression of CKD.
5.1 Target dietary protein intake for people with diabetes and CKD
stages 1–4 should be the RDA of 0.8 g/kg body weight per day. (B)
BACKGROUND
Nutritional management for people with diabetes has traditionally
focused on blood glucose control. However, dietary protein intake at all
stages of CKD appears to have an important impact in this population. If
dietary protein is limited, adequate caloric intake must be maintained by
increasing calories from carbohydrates and/or fats. Competing needs for
nutritional management of hyperglycemia, hypertension, and
dyslipidemia can make determination of appropriate protein intake
challenging. Furthermore, the diet for diabetes and CKD should consider
the qualitative, as well as the quantitative, aspects of proteins,
carbohydrates, and fats. To address dietary recommendations for people
with diabetes and CKD stages 1 to 4, studies evaluating interventions
that reduced or altered sources of dietary protein and other nutrients
were reviewed. Dietary recommendations for CKD stage 5 are provided
in the KDOQI™ CPGs for Nutrition in Chronic Renal Failure.
RATIONALE
A dietary protein intake of 0.8 g/kg body weight per day, the RDA for
this macronutrient, is a level that has been achieved in studies of
diabetes and CKD. Reduction in albuminuria and stabilization of kidney
function have been reported with dietary protein intake at the RDA
level. Nutrition surveys indicate that most people eat in excess of the
RDA for dietary protein. (Moderate)
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The same 24-h urine collection should also be used to
examine 24-h urinary creatinine (to estimate muscle mass
and to calculate 24-h creatinine clearance), potassium
(target <2-3 g/day), phosphorus (target <1,000 mg/day),
sodium (target <1.5-2 g/day although some coauthors
suggest <3 g/day) and fluid intake (<1-1.5 liters/day). If
the eDPI is >0.8 g/kg/day, more dietary counseling
including higher intake of vegetarian meals may be
considered. If the intake is <0.6 g/kg/day or if there are
signs of PEW, oral nutritional supplementation with prod-
ucts specially designed for CKD should be considered.
Because adequate calorie intake is needed to spare protein
and prevent vitamin and mineral deficiencies, it is import-
ant to assure a dietary energy intake of at least 30–35 Cal/
kg/day to avoid energy malnutrition.
In addition, it is important to assure provision of
essential amino acids in form of HBV proteins, which in-
clude almost all animal protein sources (e.g., meats and
dairy), and select plants (e.g., soybeans, quinoa) (Table 1).
Note that this may be less protein than might be
expected. For example, a 70-kg patient would require
approximately 21 g/day of HBV protein (0.3 g/kg/day),
which can be met by a single 3-oz serving of meat
(about the size of a deck of cards). Protein supplementa-
tion by a variety of different methods has been shown to
be effective in improving markers of PEW (for an
exhaustive review see reference number [19]), and given
the very robust association of these markers with poor
outcomes, a strong case can be made in favor of such
nutritional interventions. Importantly, optimal dietary
protein can usually correct PEW irrespective of its
etiology, as is the case for the strong argument behind
the provision of nutritional support in cancer cachexia
that is often engendered as a result of malignant disease
and its associated pro-inflammatory cytokines and much
less due to inadequate nutrition [20, 21].
A spontaneous reduction in protein intake as a result
of anorexia in patients with reduced kidney function can
be considered an adaptive process meant to alleviate the
short-term consequences of the body’s inability to
handle protein breakdown products [6]. The MDRD
study detected small, but significant decreases in weight
and serum concentrations of albumin, transferrin, and
cholesterol associated with protein restriction; these
were alluded to, but were not presented in detail in the
original publication [22]. Furthermore, a study examining
the incidence of ESRD and mortality after long-term
observational follow-up of patients enrolled in MDRD
study 2 (LPD vs. VLPD) indicated no significant difference
in the incidence of ESRD, but a significantly higher
mortality rate [adjusted hazard ratio (95 % CI): 1.92 (1.15to 3.20)] in patients who had been randomized to the
VLPD [23]. Due to such concerns, the focus has shifted to
strategies designed to implement moderate protein re-
striction along with other measures to offset any effect
towards PEW while maintaining its putative benefits.
Attitudes of American practitioners towards a low
protein diet
There are currently no data regarding the North
American nephrologists’ and dietitians’ attitudes and
perceptions of a LPD, although anecdotal reports suggest
that the LPD is poorly received in the USA. This is des-
pite the fact that multiple guidelines such as the Kidney
Disease Outcome Quality Initiative (KDOQI) guidelines
regarding dietary protein intake in diabetic kidney dis-
ease, developed by the National Kidney Foundation
(NKF) of the USA in 2007 [24], suggests a dietary pro-
tein intake of 0.8 g/kg/day (see Table 2). A low protein
intake is also a sustained recommendation of the na-
tional US Veterans Affairs (VA) and Department of
Defense (DoD) clinical practice guideline for the man-
agement of patients with chronic kidney disease in pri-
mary care. (available at http://www.healthquality.va.gov/
guidelines/CD/ckd/VADoDCKDCPG.pdf ) Lastly, this is
the same dietary protein intake recommended for all
Americans by the US dietary guidelines. Attitudes and
Table 3 Pilot survey of nephrologists from the Veterans Administration health system (based on 16 preliminary sets of responses)
Question 1: Do you
recommend or practice LPD?
Question 2: Will you be
interested in implementing
and managing LPD?
Question 3: How to suggest implement LPD more effectively?
Never 13 % No 25 % Dedicated dietitian involvement needed 44 %
Rarely 56 % Maybe 56 % Need to improve patient adherence and education 19 %
Sometimes 25 % Yes 19 % Monitor protein intake including by 24-h urine 19 %
Frequently 6 % Do not favor LPD 13 %
Prioritize amino-acid and other supplements 6 %
Exact questions that were asked: Question 1: Do you recommend or implement Low Protein Diet (LPD) for conservative management of patients with moderate
to advanced CKD, e.g. limiting daily dietary protein intake to 0.6-0.8 gram/kg/day? Question 2. Will you be interested in implementing and managing Low Protein
Diet (LPD) for conservative management of CKD patients? Question 3. How do you suggest nephrologists can help implement more effectively Low Protein Diet
(LPD) protocols for management of CKD patients?
Kalantar-Zadeh et al. BMC Nephrology  (2016) 17:90 Page 6 of 11perceptions of LPD among clinicians may also differ for
patients across racial and ethnic groups, contributing to
differences observed in the general population protein
intake from NHANES (see Fig. 1). The Academy of
Nutrition and Dietetics Evidence Analysis Library
recommends similar protein restrictions in its evidence-
based CKD Medical Nutrition Therapy guidelines
published in 2010 [17].
We recently embarked on an online survey for
nephrologists practicing in Veterans Administration
medical centers. Based on responses from 16 nephrolo-
gists, 69 % of these physicians confirmed that they never
or rarely recommended LPD to their patients with CKD
(see Table 3). However, 81 % of nephrologists appeared
to be interested in learning more about this therapy. In
this survey, 44 % of the surveyed physicians suggested
that the dedicated assignment of a dietitian to their CKD
patient population is needed. The following are selected
comments in response to the survey question, “How do
you suggest nephrologists can help more effectively
implement Low Protein Diet (LPD) protocols for
management of CKD patients?” (1) “We would need
additional help and support from the clinical nutrition-
ists.” (2) “Dedicated renal dietitian … able to provide
monthly follow-up… lack of dietitian is reason this is dif-
ficult to implement ….” (3) “Would need amino acid
supplementation available in the US” (4) “… patients
have many adherence issues and hard enough to get
them to restrict potassium and very tough to get them
to do LPD.” (5) “Identifying patients based on their
clinical morbidities and working closely with nutrition
services…” (6) “Scheduled follow up with nutrition
expert and educating patients to maintain food diary…”
(7) “Monitoring protein intake by 24-h urine collec-
tion…” (8) “Biggest barrier is dietitian involvement for
education, teaching, and follow up monitoring…” (9)
“Not useful except in highly motivated patients.” (10)
“It’s really difficult for our patients to follow a low-
protein diet.” (11) “MDRD study was essentially
negative.” (12) “… patients are already malnourishednear stage 5 and would not want to further impair their
nutritional status.” (13) “… however, low protein diet
may be important for a subset of CKD patients.” (14)
“Since there is limited data on the efficacy of these diets
in slowing progression – though may delay uremia – …
first priority is adherence to medication and then if pa-
tient is able/willing … refer for LPD if not malnour-
ished.” (15) “Limiting protein with monitoring for signs
of malnutrition…” (16) “… the benefits of a low protein
diet in slowing progression of CKD is minor particularly
in more advanced CKD… would worry that the patients
may become malnourished unless … followed very
closely.” (17) “Anorexia and malnutrition are a big
issue… cutting back can deeply malnourish a patient.”
(18) “For diabetics, this is another impossible dietary im-
position for minimal benefit.” (19) “Unclear if patients
are actually adherent to the diet … think of how many
are adherent to a low sodium diet…. too difficult to
implement.” (20) “… mention to patients that it may
work and … refer them to dietitian … <5 % are inter-
ested.” (21) “Maybe for the nephrotic syndrome
patients.” (22) “To control uremia, … [low protein] diet
only and it helped avoid [serum urea nitrogen]
>100 mg/dL.” (23) “… patients did not fare well.” (24)
“… tell patients to limit portion size and red meat as
part of general health. … not convinced that LPD is
useful outside of MDRD type intervention with lots of
dietitian follow up.” (see Table 3 for summary of data).
Supplemented protein restriction: can we have It
both ways?
An effective strategy to enhance the salutary effects of a
LPD is to assure that at least 50 % of the daily protein in-
take is of a HBV protein source such as dairy products,
while the rest can be vegetarian (see Table 1). Another im-
portant consideration is provision of adequate energy
along with the LPD, i.e., 30 to 35 Cal/kg/day [6]. Whereas
a LPD can be implemented by adhering to dietary restric-
tion, disease-specific, hypercaloric oral supplements may
enhance the therapy without causing malnutrition. This
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substitutes that are manufactured to assure HBV and ad-
equate energy intake. Some practitioners may be aware of
certain commercial products used for non-dialysis CKD
management, including a commercial product known as
Suplena® (Abbott Nutrition Abbott Laboratories,
Columbus OH, also known as Nepro LP® in some other
countries [LP stands for Low Protein], not to be confused
with Nepro HP® or simply Nepro® [Abbott Nutrition
Abbott Laboratories, Columbus OH] in the USA [HP
stands for High Protein]), a product recommended
for patients with Stage 5 CKD. These and other com-
mercially available products are designed for tube or
oral feeding as supplemental or sole-source nutrition,
and under medical supervision. They often have lower
protein content than products designed for dialysis
patients where the latter two products are still richer
in protein and calories, they have less potassium, phos-
phorus and sodium density than non-CKD specific prod-
ucts (see Table 4 for comparison of some commercially
available supplements in the US). There are very few stud-
ies that have examined the use of such oral nutritional
supplements in non-dialysis dependent patients with
CKD. In a Spanish study of 22 patients with CKD receiv-
ing a LPD (0.6 g/kg/day), half of patients also received a
portion of their prescribed dietary protein and calories via
Suplena® for 6 months [25]. In the oral supplement group
the nutritional measures were better, while their protein
intake appeared to be closer to the target LPD objective.
They also had better adherence with the therapy and had
greater preservation of renal function than the control
group [25].
Keto-analogues and amino acids in North America
Currently there are no commercially manufactured keto
acid analogues (KA) of amino acids in the US or Canada,
while there are some products with essential amino acids
[26]. Shah et al. recently published a comprehensive
review article on the use of KA in various countries, in-
cluding the US [26]. As to why there are no KAs avail-
able in US or Canada, there may be some historical
reasons, in particular the non-conclusive results of the
MDRD Study [26]. Indeed, in the MDRD study, the KAs
used for Study B (the VLPD supplemented with KAs)
were manufactured in the US in the 1980’s and early
1990’s by Ross Laboratories (Columbus, OH), which
later became Abbott Nutrition Abbott Laboratories. It
can be speculated that decisions not to pursue
commercialization of KAs in the US based upon the
negative results of the MDRD study. It appears that the
European company Fresenius Kabi (Ketosteril®, Bad
Homburg, Germany) took over the product and initiated
manufacturing and distribution of some types of KAs
outside of the US, including South East Asia, Europe,and some Latin American countries such as Mexico.
[27] In most of these countries, KAs are regulated as
drugs and are relatively expensive, while in some other
countries they are classified as dietary supplements. In
some countries such as India, several companies manu-
facture and distribute KAs with some subtle differences
(see Tables in article by Shah et al. [26] for comparison).
It is unclear as to why these products have not yet en-
tered the American market some 20 years after the
MDRD study. It is possible that the US Food and Drug
Administration (FDA) would stipulate due diligence
procedures including large scale randomized controlled
trials in order to approve their use in the US, if KAs
were to be purposed as drugs. Alternatively, these prod-
ucts could theoretically enter the US market as dietary
supplements or medical foods, which require a less rigid
regulatory pathway and would likely be less expensive.
However, approval as a dietary supplement may confound
the commercial interests of the parent companies holding
the patents to the use of KAs for treating CKD.
Whereas there remain many unanswered questions
pertaining to the business and marketing of KAs in
North America, their biological impact is a separate
topic which deserves review beyond the scope of this
article and is discussed elsewhere [28]. In summary, use
of KAs was tested in the MDRD study, where
supplementation of a VLPD with KAs and amino acids
was provided in Study 2. While the results of the MDRD
study and its secondary analyses did not suggest a clear
benefit from this strategy, it is possible that the type of
supplementation used in the MDRD study was not ideal
because the KA supplement contained excessive
amounts of tryptophan which could have led to produc-
tion of nephrotoxic metabolites [29]. Therefore, it is
possible that alternative supplementation regimens could
be more beneficial to patients with CKD.
Conclusions and dietary recommenations
The practice of nutritional management of non-dialysis
CKD patients in North America appears to be severely
hampered by the fear of PEW, which is a powerful pre-
dictor of outcomes in the entire range of CKD that can
be alleviated by assuring adequate protein and energy
intake. Many American nephrologists regard MDRD as
an entirely negative study and shy away from LPD.
Conversely, uncontrolled high protein intake can have
deleterious consequences including biochemical imbal-
ances such as hyperkalemia and hyperphosphatemia,
and also worsening metabolic acidosis, oxidative stress,
altered endothelial function, nitric oxide production, in-
sulin resistance, and glomerular hyperfiltration leading
to worsening proteinuria and uremia. Manipulation of
protein intake may result in significant clinical benefits
that could range from preservation of kidney function
Table 4 Comparisons among the nutrient values of some commercially available supplements in the USA, manufactured and
distributed by Abbott Nutrition or Nestle Nutrition. Information adapted from www.abbottnutrition.com,
www.nestlehealthscience.us/brands, and also from Rattanasompattikul et al. [32])
Suplena® (Nepro LPTN) Nepro® (Nepro HPTN) Ensure® (Original Ensure) Renalcal® Novasource® Renal
Volume, ml 237 237 237 250 237
Osmolality, mOsm/kg 780 745 630 600 800
Energy, Cal 425 425 220 500 475
Cal/mL 1.8 1.8 0.9 2.0 2.0
Volume, ml 237 237 237 250 237
Protein, g 10.6 19.1 9 8.5 21.6
% Calorie from Protein 10 % 18 % 16 % 7 % 18 %
Fat, g 22.7 22.7 6 20.5 23.8
Saturated Fat, g 2 2 5
Trans Fat, g: 0.0 0 0 0
Polyunsaturated Fat, g 4.1 4.1 2
Monounsaturated Fat, g 16.1 16 3
Cholesterol, mg 5.8 6.5 <2
Carbohydrate, g 46.4 37.9 32 73 43.5
% Calorie from Carb. 44 % 36 % 58 % 58 % 37 %
Dietary Fiber, g 3 3 <1
Sugars, g 14.8 8.4 15
Glycerine, g 2.6 2.6 -
Electrolytes and Minerals:
Sodium, mg 190 250 200 15 225
Potassium, mg 270 250 370 20 225
Calcium, mg 250 250 300 15 200
Phosphorus, mg 170 170 250 25 195
Magnesium, mg 50 50 100 5 47
Iodine, mcg 38 38 38 36
Manganese, mg 0.5 0.5 1.2 1
Copper, mg 0.5 0.5 0.5 0.5
Zinc, mg 6.4 6.4 3.7 3.5
Iron, mg 4.5 4.5 4.5 4.3
Selenium, mcg 18 18 18 12.5 26
Chromium, mcg 30 30 30 28.6
Molybdenum, mcg 19 19 38 17.9
Vitamins and Others:
L-Carnitine, mg 63 63 - 25 62.6
Taurine, mg 38 38 - 25 35.7
Energy, Calorie 425 425 220 500 475
Vitamin A, IU 750 750 1250 712
Vitamin D, IU 20 20 200 95
Vitamin E, IU 23 23 7.5 7.2
Vitamin K, mcg 20 20 20 19
Vitamin B6, mg 2.0 2.0 1.8
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Table 4 Comparisons among the nutrient values of some commercially available supplements in the USA, manufactured and
distributed by Abbott Nutrition or Nestle Nutrition. Information adapted from www.abbottnutrition.com,
www.nestlehealthscience.us/brands, and also from Rattanasompattikul et al. [32]) (Continued)
Vitamin B12, mcg 2.3 2.3 1.5
Vitamin C, mg 25 25 30 15 14.3
Folic Acid, mcg 250 250 100 150
Thiamin, mg 0.56 0.56 0.4
Riboflavin, mg 0.64 0.64 0.4
Niacin, mg 7.5 7.5 5
Biotin, mcg 120 120 75
Pantothenic acid, mg 3.8 3.8 2.5
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viation of uremia. A means to that end is restricting
dietary protein intake and supplementing diet with HBV
protein and essential nutrients and supplements that are
specifically designed for CKD patients and help deter
metabolic complications, reinforced by measures that
prevent the deleterious side effects of regular meals, e.g.
phosphorus and potassium binder medications, a low
salt diet, restricted fluid intake, and low-glycemic
nutrients for diabetic CKD patients without burnt-out
diabetes [30]. Whereas these dietary approaches may
pose the challenge of adherence in the context of high
protein diet that prevails the American mentality, they
are conceptually feasible towards achieving the same
goal. Registered dietitian support may improve adher-
ence to LPD.
Our dietary recommendations for non-dialysis CKD
patients with eGFR <45 ml/min/1.73 m2 (Stages 3b, 4
and 5, including gradually failing kidney transplants) or
proteinuria >0.5 g/day include a LPD (0.6 to 0.8 g/kg/
day) containing HBV proteins and/or amino acids and
adequate energy intake of 30–35 Cal/kg/day. Vegetarian
or alkali types of foods can be considered along with
HBV proteins or commercial supplements. Diabetic
CKD patients should also adhere to glycemic and calorie
recommendations according to pertinent guidelines if
possible although worsening hypoglycemia should be
watched closely. For non-adherent CKD patients with
dietary protein intake >0.8 g/kg/day based on urinary
urea nitrogen estimates of the 24-h urine collections or
in those with signs of PEW, we suggest the provision of
oral nutritional supplements that are specifically
designed for CKD patients. Patients with severe PEW or
episodes of superimposed AKI may need higher protein
intake (e.g. 1.2 g/kg/day or even higher, especially if
hypercatabolic and in critical condition) during the crit-
ical period or temporary dialysis treatment [31]. We
cautiously favor the expansion of the LPD practice in
North America and suggest additional studies using
these and other emerging therapies in non-dialysisdependent-CKD. As an appendix to this article we have
included some example of LPD instructions and recipes
for CKD patients, as posted by the NKF of the USA
website: https://www.kidney.org/atoz/content/lowprotrecipes
(see Additional file 1).
Additional file
Additional file 1: Example of Low Protein Diet instructions and recipes
for American CKD patients, as posted by the National Kidney Foundation
(NKF) of the USA. (DOC 46 kb)
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